<DOC>
	<DOC>NCT01382745</DOC>
	<brief_summary>The objective of this study is to demonstrate the feasibility of using Nimotuzumab and radiation in the treatment of squamous cell carcinomas of the anal canal in order to achieve a 65% local control rate with a better toxicity profile than the conventional treatment. Patients with high toxicity risks (HIV+ and fragile patients) will be selected for this study.</brief_summary>
	<brief_title>Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<criteria>For both step I and II: Patients with histologically confirmed squamous cell carcinoma of the anal canal Aged 18 years or older ECOG: 012 Adequate contraception in women of childbearing potential and for men Ability to understand and the willingness to sign a written informed consent document. HIVpositive patients with T12 anal canal tumors, or Patients with anal canal tumors not eligible for conventional chemotherapy (for example, due to age and/or comorbidities) Patients who have already started radiotherapy for anal canal cancer For step II: HIVpositive patients with T1, T2 anal canal tumors HIVnegative patients not eligible for conventional chemotherapy (for example, due to age and/or comorbidities) HIVnegative patients with T12 anal canal cancer For both step I and II: Patients receiving any other investigational agents Previous treatment with antiEGFR drugs History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nimotuzumab or other agents used in study. Previously treated with pelvic radiotherapy. Lesions not suitable for radiotherapy Patients with uncontrolled hypercalcemia Uncontrolled intercurrent illness Pregnant or breastfeeding women Any concurrent active malignancy Patients with T34 anal canal tumors or patients with nodes positive. Step I: HIVnegative patients with anal canal tumors that are judged suitable for current treatment consisting in radiotherapy and 5FU and MMC chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>